RAPT Therapeutics, Inc. (RAPT) Equity Average (2020 - 2024)
RAPT Therapeutics (RAPT) has disclosed Equity Average for 5 consecutive years, with $102.4 million as the latest value for Q3 2024.
- Quarterly Equity Average fell 45.04% to $102.4 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $102.4 million through Sep 2024, down 45.04% year-over-year, with the annual reading at $196.1 million for FY2023, 9.12% down from the prior year.
- Equity Average hit $102.4 million in Q3 2024 for RAPT Therapeutics, down from $120.0 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $232.8 million in Q1 2023 to a low of $97.9 million in Q1 2021.
- Historically, Equity Average has averaged $162.9 million across 5 years, with a median of $168.5 million in 2022.
- Biggest five-year swings in Equity Average: skyrocketed 81.24% in 2021 and later crashed 45.04% in 2024.
- Year by year, Equity Average stood at $107.1 million in 2020, then surged by 81.24% to $194.1 million in 2021, then rose by 11.9% to $217.2 million in 2022, then fell by 26.39% to $159.9 million in 2023, then plummeted by 35.99% to $102.4 million in 2024.
- Business Quant data shows Equity Average for RAPT at $102.4 million in Q3 2024, $120.0 million in Q2 2024, and $138.9 million in Q1 2024.